Investor Notice: Robbins LLP Informs Investors of the ImmunityBio, Inc. Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. for allegedly misleading investors about its lead product candidate, Anktiva, during the period from January 19, 2026, to March 25, 2026 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Soon-Shiong, the defendant, materially overstated Anktiva's capabilities, leading to misleading impressions about its effectiveness [2]. - A warning letter from the U.S. Food and Drug Administration (FDA) was publicized on March 24, 2026, indicating that promotional communications created a misleading impression that Anktiva could cure and prevent all cancer [3]. - Following the FDA warning, ImmunityBio's stock price fell by $1.98 per share, or 21%, closing at $7.42 per share on March 24, 2026 [3]. Group 2: Legal Proceedings and Participation - Shareholders who wish to participate in the class action can contact Robbins LLP, and those interested in serving as lead plaintiffs are encouraged to reach out [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - ImmunityBio, Inc. is a biotechnology company, with Anktiva being its lead biologic product aimed at treating a specific type of bladder cancer [1].